Pub Date : 2024-07-29DOI: 10.1080/14796694.2024.2358670
Alexander J Stratigos, Chieh-I Chen, Cristina Ivanescu, Karl D Lewis, Ketty Peris, Oliver Bechter, James Harnett, Vera Mastey, Matthew Reaney, Christina Daskalopoulou, Patrick R LaFontaine, Gerasimos Konidaris, Denise Bury, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Timothy Bowler, Matthew G Fury, Aleksandar Sekulic
Aim: To evaluate health-related quality of life (HRQoL) in cemiplimab-treated patients with locally advanced basal cell carcinoma (laBCC).Materials & methods: Eighty-four patients with laBCC received cemiplimab 350 mg every 3 weeks (up to 9 cycles). HRQoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Core 30 (QLQ-C30) and Skindex-16 questionnaires at baseline and each cycle. Mixed-effects repeated-measures models evaluated change from baseline across cycles.Results: Clinically meaningful improvement or maintenance was reported by 62-90% of patients on QLQ-C30 scales and by approximately 80% on Skindex-16 scales at Cycle 2, with consistent results at Cycle 9 except fatigue.Conclusion: Most cemiplimab-treated patients with laBCC reported improvement or maintenance of HRQoL with low symptom burden except fatigue.Clinical Trial Registration: ClinicalTrials.gov identifier NCT03132636, registered 28 April 2017.
{"title":"Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial.","authors":"Alexander J Stratigos, Chieh-I Chen, Cristina Ivanescu, Karl D Lewis, Ketty Peris, Oliver Bechter, James Harnett, Vera Mastey, Matthew Reaney, Christina Daskalopoulou, Patrick R LaFontaine, Gerasimos Konidaris, Denise Bury, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Timothy Bowler, Matthew G Fury, Aleksandar Sekulic","doi":"10.1080/14796694.2024.2358670","DOIUrl":"10.1080/14796694.2024.2358670","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate health-related quality of life (HRQoL) in cemiplimab-treated patients with locally advanced basal cell carcinoma (laBCC).<b>Materials & methods:</b> Eighty-four patients with laBCC received cemiplimab 350 mg every 3 weeks (up to 9 cycles). HRQoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Core 30 (QLQ-C30) and Skindex-16 questionnaires at baseline and each cycle. Mixed-effects repeated-measures models evaluated change from baseline across cycles.<b>Results:</b> Clinically meaningful improvement or maintenance was reported by 62-90% of patients on QLQ-C30 scales and by approximately 80% on Skindex-16 scales at Cycle 2, with consistent results at Cycle 9 except fatigue.<b>Conclusion:</b> Most cemiplimab-treated patients with laBCC reported improvement or maintenance of HRQoL with low symptom burden except fatigue.<b>Clinical Trial Registration:</b> ClinicalTrials.gov identifier NCT03132636, registered 28 April 2017.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-29DOI: 10.1080/14796694.2024.2373681
Umang Swami, Agnes Hong, Brandon Diessner, Christopher Young, Scott H Bunner, Bin Xie, Krishnan Ramaswamy, Benjamin Chastek, Nader El Chaar, Sumati Gupta
Aim: Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival outcomes in patients with nmCRPC. Patients & methods: This retrospective cohort study used Optum database electronic health records of patients with nmCRPC from 1 January 2007 to 31 December 2020 in the US. Results: Of 1955 patients, >80% received androgen-deprivation therapy (ADT) alone or ADT + first-generation nonsteroidal antiandrogen (NSAA) as first-line treatment, while only 8.24% received ADT + ARPI. ADT + ARPI remained underutilized even among those with high-risk nmCRPC. Further, ADT + NSAA had no survival benefit compared with ADT alone. Conclusion: Practice-improvement strategies are needed for treatment intensification with ARPIs for patients with nmCRPC.
{"title":"Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States.","authors":"Umang Swami, Agnes Hong, Brandon Diessner, Christopher Young, Scott H Bunner, Bin Xie, Krishnan Ramaswamy, Benjamin Chastek, Nader El Chaar, Sumati Gupta","doi":"10.1080/14796694.2024.2373681","DOIUrl":"https://doi.org/10.1080/14796694.2024.2373681","url":null,"abstract":"<p><p><b>Aim:</b> Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival outcomes in patients with nmCRPC. <b>Patients & methods:</b> This retrospective cohort study used Optum database electronic health records of patients with nmCRPC from 1 January 2007 to 31 December 2020 in the US. <b>Results:</b> Of 1955 patients, >80% received androgen-deprivation therapy (ADT) alone or ADT + first-generation nonsteroidal antiandrogen (NSAA) as first-line treatment, while only 8.24% received ADT + ARPI. ADT + ARPI remained underutilized even among those with high-risk nmCRPC. Further, ADT + NSAA had no survival benefit compared with ADT alone. <b>Conclusion:</b> Practice-improvement strategies are needed for treatment intensification with ARPIs for patients with nmCRPC.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-29DOI: 10.1080/14796694.2024.2368450
Lucia Masarova, Srdan Verstovsek, Tom Liu, Sumati Rao, Gautam Sajeev, Mirko Fillbrunn, Ryan Simpson, Weilong Li, Joseph Yang, Yvette Le Lorier, Boris Gorsh, James Signorovitch
Aim: To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol. Methods: Cost and time burden were calculated based on the transfusion status of patients in the MOMENTUM trial and estimates extracted from previous studies. Results: Reductions in transfusion associated with momelotinib are projected to result in cost and time savings compared with danazol in transfusion-dependent and transfusion-independent/requiring patients with myelofibrosis, respectively: annual medical costs ($53,143 and $46,455 per person), outpatient transfusion costs ($42,021 and $8,370 per person) and annual time savings (173 and 35 h per person). Conclusion: Fewer transfusions with momelotinib are projected to result in cost and time savings in patients with myelofibrosis and anemia compared with danazol.
{"title":"Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.","authors":"Lucia Masarova, Srdan Verstovsek, Tom Liu, Sumati Rao, Gautam Sajeev, Mirko Fillbrunn, Ryan Simpson, Weilong Li, Joseph Yang, Yvette Le Lorier, Boris Gorsh, James Signorovitch","doi":"10.1080/14796694.2024.2368450","DOIUrl":"https://doi.org/10.1080/14796694.2024.2368450","url":null,"abstract":"<p><p><b>Aim:</b> To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol. <b>Methods:</b> Cost and time burden were calculated based on the transfusion status of patients in the MOMENTUM trial and estimates extracted from previous studies. <b>Results:</b> Reductions in transfusion associated with momelotinib are projected to result in cost and time savings compared with danazol in transfusion-dependent and transfusion-independent/requiring patients with myelofibrosis, respectively: annual medical costs ($53,143 and $46,455 per person), outpatient transfusion costs ($42,021 and $8,370 per person) and annual time savings (173 and 35 h per person). <b>Conclusion:</b> Fewer transfusions with momelotinib are projected to result in cost and time savings in patients with myelofibrosis and anemia compared with danazol.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-29DOI: 10.1080/14796694.2024.2355079
Alessandra Tedeschi, Constantine S Tam, Roger G Owen, Christian Buske, Véronique Leblond, Meletios Dimopoulos, Ramón Garcia-Sanz, Jorge J Castillo, Judith Trotman, Steven P Treon, Keri Yang, Boxiong Tang, Heather Allewelt, Sheel Patel, Wai Y Chan, Aileen Cohen, Shengnan Chen, Gisoo Barnes
Aim ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM). Materials & methods: Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 and EQ-5D-5L VAS scores. Results: Overall, 201 patients (102 zanubrutinib; 99 ibrutinib) were enrolled. Clinically meaningful differences were observed in diarrhea and nausea/vomiting in both the intent-to-treat population and in patients attaining very good partial response (VGPR) in earlier cycles of treatment, as well as in long-term physical functioning and fatigue in patients achieving VGPR. Conclusion: Treatment with zanubrutinib was associated with greater improvements in health-related quality of life compared with ibrutinib in patients with WM and MYD88 mutations.Clinical Trial Registration: NCT03053440 (ClinicalTrials.gov).
ASPEN 是一项随机、开放标签的 III 期研究,比较了赞鲁替尼和伊布替尼对瓦尔登斯特伦巨球蛋白血症(WM)患者的治疗效果。材料与方法:患者报告结果为探索性终点,使用 EORTC QLQ-C30 和 EQ-5D-5L VAS 评分进行评估。结果共有 201 名患者(102 名扎鲁替尼患者;99 名伊布替尼患者)入组。在意向治疗人群和早期治疗周期中获得很好部分应答(VGPR)的患者中,观察到腹泻和恶心/呕吐方面存在有临床意义的差异;在获得 VGPR 的患者中,观察到长期身体功能和疲劳方面存在有临床意义的差异。结论在WM和MYD88突变的患者中,与伊布替尼相比,扎努鲁替尼治疗与健康相关的生活质量改善更大:NCT03053440(ClinicalTrials.gov)。
{"title":"Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.","authors":"Alessandra Tedeschi, Constantine S Tam, Roger G Owen, Christian Buske, Véronique Leblond, Meletios Dimopoulos, Ramón Garcia-Sanz, Jorge J Castillo, Judith Trotman, Steven P Treon, Keri Yang, Boxiong Tang, Heather Allewelt, Sheel Patel, Wai Y Chan, Aileen Cohen, Shengnan Chen, Gisoo Barnes","doi":"10.1080/14796694.2024.2355079","DOIUrl":"https://doi.org/10.1080/14796694.2024.2355079","url":null,"abstract":"<p><p><b>Aim</b> ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM). <b>Materials & methods:</b> Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 and EQ-5D-5L VAS scores. <b>Results:</b> Overall, 201 patients (102 zanubrutinib; 99 ibrutinib) were enrolled. Clinically meaningful differences were observed in diarrhea and nausea/vomiting in both the intent-to-treat population and in patients attaining very good partial response (VGPR) in earlier cycles of treatment, as well as in long-term physical functioning and fatigue in patients achieving VGPR. <b>Conclusion:</b> Treatment with zanubrutinib was associated with greater improvements in health-related quality of life compared with ibrutinib in patients with WM and <i>MYD88</i> mutations.<b>Clinical Trial Registration:</b> NCT03053440 (ClinicalTrials.gov).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lung cancer is one of the most common malignancies worldwide, with non-small cell lung cancer (NSCLC) being the most common type. As understanding of precise treatment options for NSCLC deepens, circulating tumor DNA (ctDNA) has emerged as a potential biomarker that has become a research hotspot and may represent a new approach for the individualized diagnosis and treatment of NSCLC. This article reviews the applications of ctDNA for the early screening of patients with NSCLC, guiding targeted therapy and immunotherapy, evaluating chemotherapy and postoperative efficacy, assessing prognosis and monitoring recurrence. With the in-depth study of the pathogenesis of NSCLC, plasma ctDNA may become an indispensable part of the precise treatment of NSCLC, which has great clinical application prospects.
{"title":"Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer.","authors":"Shenyu Zhu, Rongqian Wu, Xiangjin Liu, Bin Xie, Chunfa Xie, Shulin Li, Zhicheng Wu, Zuxiong Zhang, Zhixian Tang, Liang Gu","doi":"10.1080/14796694.2024.2376513","DOIUrl":"https://doi.org/10.1080/14796694.2024.2376513","url":null,"abstract":"<p><p>Lung cancer is one of the most common malignancies worldwide, with non-small cell lung cancer (NSCLC) being the most common type. As understanding of precise treatment options for NSCLC deepens, circulating tumor DNA (ctDNA) has emerged as a potential biomarker that has become a research hotspot and may represent a new approach for the individualized diagnosis and treatment of NSCLC. This article reviews the applications of ctDNA for the early screening of patients with NSCLC, guiding targeted therapy and immunotherapy, evaluating chemotherapy and postoperative efficacy, assessing prognosis and monitoring recurrence. With the in-depth study of the pathogenesis of NSCLC, plasma ctDNA may become an indispensable part of the precise treatment of NSCLC, which has great clinical application prospects.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-29DOI: 10.1080/14796694.2024.2377531
Kamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, Sameer Bhargava, Andliena Tahiri, Jovana Klajic, Torben Lüders, Marie Fongård, Meh Sameen Nawaz, Tatjana Bosnjak-Olsen, Unn-Cathrin Edvardsen Buvarp, Aino Katri Johanna Rosenskiold, Nam Thi Nguyen, Tone Tysko Sletbak, Manouchehr Seyedzadeh, Knut Selsås, Alina Carmen Porojnicu, Helle Kristine Skjerven, Tone Hovda, Kristine Kleivi Sahlberg, Lilly Anne Torland, Marianne Lyngra, Clara Louise Hammarström, Elma Bahonjic Hönigsperger, John Christopher Noone, Silje Mathiassen, Antoni Hurtado, Shom Goel, Andrew Koff, Xavier Tekpli, Vessela N Kristensen, Jürgen Geisler
Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be an appropriate alternative in selected patients. Thus, the NEOLETRIB trial evaluates the response of ER-positive, HER2-negative luminal A/B breast cancer to the combination of letrozole and ribociclib in the neoadjuvant setting. Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment.Trial registration number: NCT05163106 (ClinicalTrials.gov).
化疗是所有乳腺癌亚组的新辅助疗法,包括 ER 阳性和 HER2 阴性病例。不过,有研究表明,在选定的患者中,使用芳香化酶抑制剂联合 CDK4/6 抑制剂可能是一种合适的替代疗法。因此,NEOLETRIB试验评估了ER阳性、HER2阴性的管腔A/B型乳腺癌在新辅助治疗中对来曲唑和ribociclib联合治疗的反应。在6个月的治疗期间,将进行全面的分子生物学程序,包括对肿瘤活检组织进行连续单细胞RNA测序,并广泛收集血液样本、肿瘤活检组织和肠道微生物组标本。我们的研究结果有望有助于更好地选择可能从这种药物组合中获益的患者,并为了解这种治疗过程中肿瘤内部的变化提供新的视角:NCT05163106(ClinicalTrials.gov)。
{"title":"The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.","authors":"Kamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, Sameer Bhargava, Andliena Tahiri, Jovana Klajic, Torben Lüders, Marie Fongård, Meh Sameen Nawaz, Tatjana Bosnjak-Olsen, Unn-Cathrin Edvardsen Buvarp, Aino Katri Johanna Rosenskiold, Nam Thi Nguyen, Tone Tysko Sletbak, Manouchehr Seyedzadeh, Knut Selsås, Alina Carmen Porojnicu, Helle Kristine Skjerven, Tone Hovda, Kristine Kleivi Sahlberg, Lilly Anne Torland, Marianne Lyngra, Clara Louise Hammarström, Elma Bahonjic Hönigsperger, John Christopher Noone, Silje Mathiassen, Antoni Hurtado, Shom Goel, Andrew Koff, Xavier Tekpli, Vessela N Kristensen, Jürgen Geisler","doi":"10.1080/14796694.2024.2377531","DOIUrl":"https://doi.org/10.1080/14796694.2024.2377531","url":null,"abstract":"<p><p>Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be an appropriate alternative in selected patients. Thus, the NEOLETRIB trial evaluates the response of ER-positive, HER2-negative luminal A/B breast cancer to the combination of letrozole and ribociclib in the neoadjuvant setting. Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment.<b>Trial registration number:</b> NCT05163106 (ClinicalTrials.gov).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-26DOI: 10.1080/14796694.2024.2375959
Oppah Kuguyo, Alice Matimba, Mugove G Madziyire, Thulani Magwali, Collet Dandara, Charles Fb Nhachi, Nomsa Tsikai
Aim: To describe treatment-induced toxicities (TITs) and associated factors in Zimbabwean cancer patients receiving cisplatin. Methods: In total, 252 Zimbabwean women with cervical cancer, receiving cisplatin were followed up over 12 months for TITs and disease status. Results: Peripheral neuropathy (70%) and ototoxicity (53%) were most prevalent. Advanced disease (OR = 1.3; 95% CI = 1.1-1.5; p = 0.02), pain comedications (OR = 1.3; 95% CI = 1.1-1.5; p = 0.03), alcohol (OR = 2.8; 95% CI = 1.1-7.5; p = 0.04) and comorbidities (OR = 1.2; 95% CI = 1.1-1.4; p = 0.04) increased peripheral neuropathy and ototoxicity risk. Older age increased risk of disease progression (OR = 1.9; 95% CI = 1.4-3.0; p = 0.033). Conclusion: High peripheral neuropathy and ototoxicity prevalence were observed, which are not routinely monitored in Zimbabwe. There is a need for capacity building to incorporate comprehensive TIT testing and optimize cancer care in Zimbabwe.
目的:描述接受顺铂治疗的津巴布韦癌症患者的治疗诱发毒性(TITs)及相关因素。方法共对 252 名接受顺铂治疗的津巴布韦宫颈癌妇女进行了为期 12 个月的随访,以了解 TITs 和疾病状况。结果外周神经病变(70%)和耳毒性(53%)最为常见。晚期疾病(OR = 1.3;95% CI = 1.1-1.5;p = 0.02)、止痛药物(OR = 1.3;95% CI = 1.1-1.5;p = 0.03)、酒精(OR = 2.8;95% CI = 1.1-7.5;p = 0.04)和合并症(OR = 1.2;95% CI = 1.1-1.4;p = 0.04)增加了周围神经病变和耳毒性的风险。年龄越大,疾病进展风险越高(OR = 1.9;95% CI = 1.4-3.0;p = 0.033)。结论观察到外周神经病变和耳毒性发病率较高,而津巴布韦并未对其进行常规监测。津巴布韦需要进行能力建设,以纳入全面的 TIT 检测并优化癌症护理。
{"title":"Prevalence and predictors for cisplatin-induced toxicities in Zimbabwean women with cervical cancer.","authors":"Oppah Kuguyo, Alice Matimba, Mugove G Madziyire, Thulani Magwali, Collet Dandara, Charles Fb Nhachi, Nomsa Tsikai","doi":"10.1080/14796694.2024.2375959","DOIUrl":"https://doi.org/10.1080/14796694.2024.2375959","url":null,"abstract":"<p><p><b>Aim:</b> To describe treatment-induced toxicities (TITs) and associated factors in Zimbabwean cancer patients receiving cisplatin. <b>Methods:</b> In total, 252 Zimbabwean women with cervical cancer, receiving cisplatin were followed up over 12 months for TITs and disease status. <b>Results:</b> Peripheral neuropathy (70%) and ototoxicity (53%) were most prevalent. Advanced disease (OR = 1.3; 95% CI = 1.1-1.5; p = 0.02), pain comedications (OR = 1.3; 95% CI = 1.1-1.5; p = 0.03), alcohol (OR = 2.8; 95% CI = 1.1-7.5; p = 0.04) and comorbidities (OR = 1.2; 95% CI = 1.1-1.4; p = 0.04) increased peripheral neuropathy and ototoxicity risk. Older age increased risk of disease progression (OR = 1.9; 95% CI = 1.4-3.0; p = 0.033). <b>Conclusion:</b> High peripheral neuropathy and ototoxicity prevalence were observed, which are not routinely monitored in Zimbabwe. There is a need for capacity building to incorporate comprehensive TIT testing and optimize cancer care in Zimbabwe.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-24DOI: 10.1080/14796694.2024.2363131
Neeraj Agarwal, Fred Saad, Arun A Azad, Joaquin Mateo, Nobuaki Matsubara, Neal D Shore, Jayeta Chakrabarti, Hsiang-Chun Chen, Silvana Lanzalone, Alexander Niyazov, Karim Fizazi
What is this summary about?: This summary is about the ongoing research study called TALAPRO-3. This study is testing the use of two medicines called talazoparib and enzalutamide. The two medicines are being used together as a treatment for patients with a type of cancer called metastatic castration-sensitive prostate cancer and changes in specific DNA repair genes within their tumors. The study began in May 2021, and includes 599 patients from 27 countries.
What is metastatic castration-sensitive prostate cancer?: Metastatic castration-sensitive prostate cancer is known as mCSPC for short. It is cancer that has started in the prostate and spread to other body parts. The prostate is a gland below the bladder and helps make semen (the liquid that contains sperm). Castration-sensitive means that the cancer responds to treatments that lower testosterone in the blood.
Which medicines are being tested?: In this study, some patients will take talazoparib plus enzalutamide while others will take a placebo plus enzalutamide. Talazoparib and enzalutamide are two different cancer medicines. Talazoparib is not currently used to treat patients with mCSPC. Enzalutamide is used to treat patients with prostate cancer. Talazoparib plus enzalutamide is being compared with a placebo plus enzalutamide to see if patients live longer without their cancer getting worse, or them dying, when taking talazoparib plus enzalutamide or when taking a placebo plus enzalutamide.
What are the aims of the talapro-3 study?: This study aims to find out if treatment with talazoparib plus enzalutamide increases the length of time the patients in the study live without their cancer getting worse, or them dying, compared with treatment with a placebo plus enzalutamide. The study will also measure how long the patients in the study live, the number and types of side effects they have, their general health and quality of life, and whether there are changes in how patients report their pain.Clinical Trial Registration: NCT03395197 (TALAPRO-2) (ClinicalTrials.gov).
{"title":"The TALAPRO-3 study design: a plain language summary.","authors":"Neeraj Agarwal, Fred Saad, Arun A Azad, Joaquin Mateo, Nobuaki Matsubara, Neal D Shore, Jayeta Chakrabarti, Hsiang-Chun Chen, Silvana Lanzalone, Alexander Niyazov, Karim Fizazi","doi":"10.1080/14796694.2024.2363131","DOIUrl":"https://doi.org/10.1080/14796694.2024.2363131","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This summary is about the ongoing research study called TALAPRO-3. This study is testing the use of two medicines called talazoparib and enzalutamide. The two medicines are being used together as a treatment for patients with a type of cancer called metastatic castration-sensitive prostate cancer and changes in specific DNA repair genes within their tumors. The study began in May 2021, and includes 599 patients from 27 countries.</p><p><strong>What is metastatic castration-sensitive prostate cancer?: </strong>Metastatic castration-sensitive prostate cancer is known as mCSPC for short. It is cancer that has started in the prostate and spread to other body parts. The prostate is a gland below the bladder and helps make semen (the liquid that contains sperm). Castration-sensitive means that the cancer responds to treatments that lower testosterone in the blood.</p><p><strong>Which medicines are being tested?: </strong>In this study, some patients will take talazoparib plus enzalutamide while others will take a placebo plus enzalutamide. Talazoparib and enzalutamide are two different cancer medicines. Talazoparib is not currently used to treat patients with mCSPC. Enzalutamide is used to treat patients with prostate cancer. Talazoparib plus enzalutamide is being compared with a placebo plus enzalutamide to see if patients live longer without their cancer getting worse, or them dying, when taking talazoparib plus enzalutamide or when taking a placebo plus enzalutamide.</p><p><strong>What are the aims of the talapro-3 study?: </strong>This study aims to find out if treatment with talazoparib plus enzalutamide increases the length of time the patients in the study live without their cancer getting worse, or them dying, compared with treatment with a placebo plus enzalutamide. The study will also measure how long the patients in the study live, the number and types of side effects they have, their general health and quality of life, and whether there are changes in how patients report their pain.<b>Clinical Trial Registration:</b> NCT03395197 (TALAPRO-2) (ClinicalTrials.gov).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-23DOI: 10.1080/14796694.2024.2370236
Hongming Liu, Weixun Xie, Weihua Gong
Malignant tumors including gastric cancer (GC) are the leading cause of deaths among reproductive women. Physiological morning sickness can mask the clinical manifestations of GC, whereas the clinical presence of metastatic tumors in the abdominal cavity may be easily mistaken for abdominal swelling caused by fetal growth. Pregnancy and delivery processes in young females could accelerate the growth of GC, leading to its rapid development and grave prognosis. Therefore, early diagnosis is critical and gastrointestinal endoscopy is recommended for any suspected pregnant woman with long-term morning sickness. Treatment strategies, including chemotherapy, resection surgery and radiotherapy, will be determined based on a comprehensive consideration of the status of both the fetus and the mother. Rational management, especially clinical multidisciplinary collaboration may significantly benefit such patients.
{"title":"Gastric cancer in pregnancy: a review.","authors":"Hongming Liu, Weixun Xie, Weihua Gong","doi":"10.1080/14796694.2024.2370236","DOIUrl":"https://doi.org/10.1080/14796694.2024.2370236","url":null,"abstract":"<p><p>Malignant tumors including gastric cancer (GC) are the leading cause of deaths among reproductive women. Physiological morning sickness can mask the clinical manifestations of GC, whereas the clinical presence of metastatic tumors in the abdominal cavity may be easily mistaken for abdominal swelling caused by fetal growth. Pregnancy and delivery processes in young females could accelerate the growth of GC, leading to its rapid development and grave prognosis. Therefore, early diagnosis is critical and gastrointestinal endoscopy is recommended for any suspected pregnant woman with long-term morning sickness. Treatment strategies, including chemotherapy, resection surgery and radiotherapy, will be determined based on a comprehensive consideration of the status of both the fetus and the mother. Rational management, especially clinical multidisciplinary collaboration may significantly benefit such patients.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-23DOI: 10.1080/14796694.2024.2376512
Ziyuan Shen, Xudong Zhang, Yujie Li, Xicheng Chen, Xing Xing, Hao Zhang, Jingjing Ye, Ling Wang, Tao Jia, Taigang Zhu, Yuqing Miao, Chunling Wang, Hui Liu, Liang Wang, Wei Sang
Aim: This multicenter retrospective study aimed to develop a novel prognostic system for extranodal natural killer/T-cell lymphoma (ENKTL) patients in the era of pegaspargase/L-asparaginase. Materials & methods: A total of 844 newly diagnosed ENKTL patients were included. Results: Multivariable analysis confirmed that Eastern Cooperative Oncology Group performance status, lactate dehydrogenase, Chinese Southwest Oncology Group and Asia Lymphoma Study Group ENKTL (CA) system, and albumin were independent prognostic factors. By rounding up the hazard ratios from four significant variables, a maximum of 7 points were assigned. The model of Huaihai Lymphoma Working Group-Natural killer/T-cell Lymphoma prognostic index (NPI) was identified with four risk groups and the 5-year overall survival was 88.2, 66.7, 54.3 and 30.5%, respectively. Conclusion: Huaihai Lymphoma Working Group-NPI provides a feasible stratification system for patients with ENKTL in the era of pegaspargase/L-asparaginase.
{"title":"A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginase.","authors":"Ziyuan Shen, Xudong Zhang, Yujie Li, Xicheng Chen, Xing Xing, Hao Zhang, Jingjing Ye, Ling Wang, Tao Jia, Taigang Zhu, Yuqing Miao, Chunling Wang, Hui Liu, Liang Wang, Wei Sang","doi":"10.1080/14796694.2024.2376512","DOIUrl":"https://doi.org/10.1080/14796694.2024.2376512","url":null,"abstract":"<p><p><b>Aim:</b> This multicenter retrospective study aimed to develop a novel prognostic system for extranodal natural killer/T-cell lymphoma (ENKTL) patients in the era of pegaspargase/L-asparaginase. <b>Materials & methods:</b> A total of 844 newly diagnosed ENKTL patients were included. <b>Results:</b> Multivariable analysis confirmed that Eastern Cooperative Oncology Group performance status, lactate dehydrogenase, Chinese Southwest Oncology Group and Asia Lymphoma Study Group ENKTL (CA) system, and albumin were independent prognostic factors. By rounding up the hazard ratios from four significant variables, a maximum of 7 points were assigned. The model of Huaihai Lymphoma Working Group-Natural killer/T-cell Lymphoma prognostic index (NPI) was identified with four risk groups and the 5-year overall survival was 88.2, 66.7, 54.3 and 30.5%, respectively. <b>Conclusion:</b> Huaihai Lymphoma Working Group-NPI provides a feasible stratification system for patients with ENKTL in the era of pegaspargase/L-asparaginase.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}